Skip to content

The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

The Role and Mechanism of GPER Hippo Pathway in Regulating Uterine Arterial Smooth Muscle CBS/H2S in the Pathogenesis of Preeclampsia

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06205771
Enrollment
54
Registered
2024-01-16
Start date
2024-04-10
Completion date
2029-12-31
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Keywords

preeclampsia

Brief summary

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are: * The pathological significance of GPER in uterine artery dilation in preeclampsia * The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Detailed description

1. Measure the content of H2S in uterine arterial smooth muscle and circulation of normal pregnancy and PE pregnant women, and analyze the relationship between the content of H2S in uterine arterial smooth muscle and circulation of PE pregnant women and PE. 2. Knock down the GPER and overexpression of GPER in HTR-8 cells, and detect the expression of GPER, CBS, and Hippo pathway related proteins using Western blot and qRT-PCR to verify the efficiency of knockdown and overexpression. Use different concentrations of H2S donor (GYY4137) to interfere with HTR-8 cells after treatment, and use RT-PCR and Western blot to detect the mRNA and protein expression of downstream molecules YAP and TAZ in Hippo pathway in cells, respectively.

Interventions

OTHERH2S content

H2S content

Sponsors

Hao Feng
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman 2. Pregnant women undergoing lower segment cesarean section for delivery

Exclusion criteria

1. Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases; 2. Multiple pregnancy 3. Pregnant women undergoing vaginal delivery 4. Normal pregnant women who are\<37 weeks or\>40 weeks pregnant

Design outcomes

Primary

MeasureTime frameDescription
H2S content in uterine arterial smooth muscle circulation8:00 amH2S content in circulation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026